ARS PHARMACEUTICALS INC
SPRYNASDAQ🏆 #3106 by market capEarnings Nov 17 · PostUS Equity
$3.65▼ $0.08 (−2.14%)
Pre-market · at closeTrack SPRY
Get earnings, price moves & breaking news on Telegram
24h▼ 2.1%
7d▼ 15.3%
14d▼ 9.9%
30d▼ 17.2%
ytd▼ 68.7%
1y▼ 59.3%
🏦Market Cap
$363M
Small Cap
📈Revenue Growth (YoY)
4.1%
Slowing
📊Gross Margin
71.4%
High
💵FCF Margin
—
⚖️P/S Ratio
3.1x
Fair
Otter Score
64
Fair
Trading Snapshot
- Day Range
- $3.53 – $3.73
- 52-Week Range
- $3.64 – $13.15
- Volume (shares)
- 185,784
- Avg Volume (shares)
- —
- Shares Outstanding
- 99.5M
- Next Earnings
- 2026-11-17
Fundamentals Snapshot
- Annual Revenue
- $84M
- Last Q Revenue
- $34M
- P/E Ratio
- —
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-2.17
- Dividend Yield
- —
- Dilution (1yr)
- +0.6%
ARS PHARMACEUTICALS INC
SPRYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$84M▼ −5.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.8%▼ −1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$179M▲ +5720.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$171M▼ −1418.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
98.6M▲ +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$55M▼ −$106M YoY
StockOtter · stockotter.spaceAbout ARS PHARMACEUTICALS INC
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy5
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.